drugset / Trial / NCT00453687

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.

NCT00453687

Phase 1 Completed 12 enrolled GlaxoSmithKline
RandomizedSingle-groupDouble-blindTreatment

Summary

This study will investigate the safety and tolerability of inhaled doses of GSK233705 with a new formulation.

Timeline

Start
2007-03-09
Primary completion
2007-05-16
Completion
2007-05-16

Publications

  • Background This study has not been published in the scientific literature.

Drugs

EvaluationDrugModalityDoseRoute
Subject DAROTROPIUM Small molecule 50 ug Inhaled
Subject DAROTROPIUM Small molecule 100 ug Inhaled
Subject DAROTROPIUM Small molecule 200 ug Inhaled